Table 1 Patient demographic, disease, and treatment characteristics
| Â | IMN Treated | IMN Untreated |
|---|---|---|
Patient Characteristics | ||
 Total (n) | 16 | 33 |
 Median Age (Range), years | 47.4 (36.9–69.9) | 48 (26.5–69.1) |
Disease Characteristics | ||
 Stage | ||
  II | 5 (31.3%) | 21 (63.6%) |
  III | 11 (68.8%) | 12 (36.4%) |
 Node Positive | 12 (75%) | 25 (75.8%) |
 Cell Type | ||
  Ductal | 12 (75%) | 30 (90.9%) |
  Lobular | 4 (25%) | 3 (9.1%) |
 Receptor Status | ||
  ER+ | 13 (81.3%) | 28 (84.8%) |
  PR+ | 12 (75%) | 24 (72.7%) |
  HER2/neu+ | 2 (12.5%) | 6 (18.2%) |
  Triple Negative | 2 (12.5%) | 3 (9.1%) |
Treatment Characteristics | ||
 Surgery | ||
  Mastectomy | 15 (93.8%) | 21 (63.6%) |
  Lumpectomy | 1 (6.3%) | 12 (36.4%) |
 Chemotherapy | ||
  Neoadjuvant | 6 (37.5%) | 14 (42.4%) |
  Adjuvant | 10 (67.5%) | 12 (36.4%) |
  None | 0 (0%) | 7 (21.2%) |
 Radiotherapy Coverage | ||
|  | BR + SCF + IMN: 14 (87.5%) | BR + SCF: 12 (36%) |
|  | CW + SCF + IMN: 1 (6.3%) | CW + SCF: 17 (52%) |
|  | TE + SCF + IMN: 1 (6.3%) | TE + SCF: 4 (12%) |
 Median Dose (Range), Gy | ||
  IMN | 50.4 (50.4) | N/A |
  SCF | 50.4 (45–50.4) | 50.4 (45–50.4) |
  BR/CW/TE | 50.4 (50.4) | 50.4 (50–50.4) |